7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one, Salts thereof And Methods of Using The Same in Combination Therapy
AssigneeOncoceutics, Inc.
InventorsMartin STOGNIEW, Joshua E. ALLEN
Life of this patent
Estimating the term…
Abstract
This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
Claims21
A method of treatment, comprising administering to a subject in need of such treatment:
- (i) a first therapeutic agent including compound (1):
- or a pharmaceutically acceptable salt thereof in combination with (ii) a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
A composition comprising a therapeutic agent including compound (2):
A method of treatment, which comprises administering to a subject in need of such treatment a combination of a first therapeutic agent and a second therapeutic agent, the method comprising:
- (i) administering to the subject the first therapeutic agent including compound (1):
- or a pharmaceutically acceptable salt thereof;
- (ii) monitoring level of compound (1) or a pharmaceutically acceptable salt thereof or a metabolite thereof in the subject using pharmacokinetic profiling, wherein dosing of compound (1) or a pharmaceutically acceptable salt thereof is selected to such that maximum concentration of compound (1) or a pharmaceutically acceptable salt thereof in blood (whole blood, plasma, or serum) is maintained at a value less than 1500 ng/dl for a therapeutic time period;
- and
- (iii) administering the second therapeutic agent conditional on the level of the first therapeutic agent in the subject.
A method of treatment, which comprises administering to a subject in need of such treatment a combination of a first therapeutic agent and a second therapeutic agent, the method comprising:
- (i) administering to the subject the first therapeutic agent including compound (1):
- or a pharmaceutically acceptable salt thereof;
- (ii) monitoring level of compound (1) or a pharmaceutically acceptable salt thereof or a metabolite thereof in the subject using pharmacokinetic profiling, wherein dosing of compound (1) or a pharmaceutically acceptable salt thereof is selected to maintain maximum concentration of compound (1) or a pharmaceutically acceptable salt thereof in blood (whole blood, plasma, or serum) of the subject between about 85 ng/dl and 1500 ng/dl for a therapeutic time period;
- and
- (iii) administering the second therapeutic agent conditional on the level of the first therapeutic agent in the subject.
A composition for use in a treatment, the composition comprising, separately or together, (i) a first therapeutic agent including compound (1):
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) at least one second therapeutic agent, for simultaneous, sequential or separate administration to a subject in need of such treatment.
A composition for use in a treatment, the composition comprising, separately or together, (i) a first therapeutic agent including compound (1):
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) at least one second therapeutic agent, for sequential administration to a subject in need of such treatment, wherein administration of the second therapeutic agent is conditioned on the level of the first therapeutic agent in the subject.
Dependencies are inferred from the claim text.